All In Biotech

Drug Trial Radar · NCT00048568

A Phase III Study of Abatacept (BMS-188667) in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate

A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study and Open-Label Study to Evaluate the Efficacy and Safety of Abatacept in Combination Therapy With Methotrexate Versus Methotrexate Alone in Subjects With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate

Last checked: Nov 20, 2026Latest source record: Dec 5, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,250 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,250

Actual

Start

Dec 2002

Primary completion

Oct 2009

Study completion Oct 2009

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Nov 13, 2002

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Short Term: The purpose of this clinical research study is to learn if abatacept (BMS-188667) in combination with methotrexate is better than methotrexate alone in participants that have active rheumatoid arthritis and are not responding to methotrexate. The safety of this treatment will also be studied. Long Term Extension: The purpose of this amendment is to provide participants who have completed the initial 12-month double-blind treatment period the opportunity to receive open label treatment with active drug treatment until abatacept is approved in the local country or until clinical development has been discontinued.

Conditions

  • Rheumatoid Arthritis

Interventions

  • AbataceptDrug

    Intravenous (IV) Solution, - Weight Titered (500 mg \< 60 kg); (750 mg 60-100 kg), )1 gram \> 100 kg), Day 1, Day 15, Day 29; every 28 days thereafter, 1 year

  • MethotrexateDrug

    Tablets, Oral, \>= 15 mg, weekly, 1 year

  • PlaceboDrug

    IV solution, Intravenous, D5W, Day 1, Day 15, Day 29; every 28 days thereafter, 1 year

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of American College of Rheumatology 20 (ACR 20) Responders at Day 169Time frame: Day 169
  2. Number of Participants Achieving Clinically Meaningful Improvement in Health Assessment Questionnaire (HAQ) at Day 365Time frame: Day 365
  3. Baseline and Mean Change From Baseline (BL) in Radiographic Erosion Score Results at Day 365Time frame: BL (Day 0), Day 365
  4. Participants With Deaths, Adverse Events (AEs) and SAEs in the Open-Label (OL) PeriodTime frame: Day 365 to Day 2,185
  5. Participants With Hematology Values Meeting the Marked Abnormality Criteria in the OL PeriodTime frame: Day 365 to Day 2,185
  6. Participants With Liver and Kidney Function Values Meeting the Marked Abnormality Criteria in the OL PeriodTime frame: Day 365 to Day 2,185
  7. Participants With Electrolyte Values Meeting the Marked Abnormality Criteria in the OL PeriodTime frame: Day 365 to Day 2,185
  8. Participants With Glucose, Protein, Metabolites, and Urinalysis Values Meeting the Marked Abnormality Criteria in the OL PeriodTime frame: Day 365 to Day 2,185
  9. Mean BL Immunoglobulins Over Time in the OL PeriodTime frame: BL (Day 0), Day 365, Day 729, Day 1,093
  10. Mean Change From BL in Immunoglobulins in the OL PeriodTime frame: BL (Day 0), Day 365, Day 729, Day 1,093
  11. Participants With Immunogenicity to Abatacept in the Cumulative DB + OL PeriodTime frame: Day 1 to Day 1,821
  12. Number of Participants Experiencing Clinically Significant Changes in Vital Signs in the OL PeriodTime frame: Day 365 to Day 1,821. All changes in participant vital signs were monitored on each day of study drug administration prior to dosing and 60 minutes after dosing.
  13. Number of Participants Experiencing AEs of Special Interest in the OL PeriodTime frame: Day 365 to Day 2,185
  14. Mean BL Hematocrit in the OL PeriodTime frame: Baseline (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,905, Day 1,989, Day 2,073, Day 2,185
  15. Mean Change From BL in Participant Hematocrit in the OL PeriodTime frame: BL (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,905, Day 1,989, Day 2,073, Day 2,185
  16. Mean BL Platelet Count in the OL PeriodTime frame: BL (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,905, Day 1,989, Day 2,073, Day 2,185
  17. Mean Change From BL in Participant Platelet Count in the OL PeriodTime frame: BL (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,905, Day 1,989, Day 2,073, Day 2,185
  18. Mean BL Hemoglobin, Total Protein, and Albumin in the OL PeriodTime frame: BL (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,905, Day 1,989, Day 2,073, Day 2,185
  19. Mean Change From BL in Hemoglobin, Total Protein, and Albumin in the OL PeriodTime frame: BL (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,905, Day 1,989, Day 2,073, Day 2,185
  20. Mean BL White Blood Cells in the OL PeriodTime frame: BL (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,905, Day 1,989, Day 2,073, Day 2,185
  21. Mean Change From BL in White Blood Cells in the OL PeriodTime frame: BL (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,905, Day 1,989, Day 2,073, Day 2,185
  22. Mean BL Liver Function Parameters in the OL PeriodTime frame: BL (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,905, Day 1,989, Day 2,073, Day 2,185
  23. Mean Change From BL in Liver Function Parameters in the OL PeriodTime frame: BL (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,905, Day 1,989, Day 2,073, Day 2,185
  24. Mean BL Select Laboratory Parameters in the OL PeriodTime frame: BL (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,905, Day 1,989, Day 2,073, Day 2,185
  25. Mean Change From BL in Select Laboratory Parameters in the OL PeriodTime frame: BL (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,905, Day 1,989, Day 2,073, Day 2,185
  26. Mean BL Serum Electrolytes in the OL PeriodTime frame: BL (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,905, Day 1,989, Day 2,073, Day 2,185
  27. Mean Change From BL in Serum Electrolytes in the OL PeriodTime frame: BL (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,905, Day 1,989, Day 2,073, Day 2,185

Locations

48 sites in 1 country. Site status is shown where the registry gives one.

  • Local Institution

    Birmingham, Alabama

  • Local Institution

    Huntsville, Alabama

  • Local Institution

    Mobile, Alabama

  • Local Institution

    Phoenix, Arizona

  • Local Institution

    Scottsdale, Arizona

  • Local Institution

    Corona, California

  • Local Institution

    Irvine, California

  • Local Institution

    La Jolla, California

  • Local Institution

    Long Beach, California

  • Local Institution

    Rancho Mirage, California

  • Local Institution

    Aurora, Colorado

  • Local Institution

    Colorado Springs, Colorado

  • Local Institution

    Denver, Colorado

  • Local Institution

    Hamden, Connecticut

  • Local Institution

    Washington D.C., District of Columbia

  • Local Institution

    Fort Lauderdale, Florida

  • Local Institution

    Gainsville, Florida

  • Local Institution

    Palm Harbor, Florida

  • Local Institution

    Sarasota, Florida

  • Local Institution

    St. Petersburg, Florida

  • Local Institution

    Chicago, Illinois

  • Local Institution

    Rockford, Illinois

  • Local Institution

    Wichita, Kansas

  • Local Institution

    Coeur d'Alene, Maryland

  • Local Institution

    Cumberland, Maryland

  • Local Institution

    Springfield, Massachusetts

  • Local Institution

    Duluth, Minnesota

  • Local Institution

    Lincoln, Nebraska

  • Local Institution

    New Brunswick, New Jersey

  • Local Institution

    Albuquerque, New Mexico

  • Local Institution

    Albany, New York

  • Local Institution

    Binghamton, New York

  • Local Institution

    Mineola, New York

  • Local Institution

    New York, New York

  • Local Institution

    Syracuse, New York

  • Local Institution

    The Bronx, New York

  • Local Institution

    Wilmington, North Carolina

  • Local Institution

    Cincinnati, Ohio

  • Local Institution

    Oklahoma City, Oklahoma

  • Local Institution

    Duncansville, Pennsylvania

Showing 40 of 48 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.